Movement Alert｜Twist Bioscience Corp Falls 5.36% in Regular Trading, Profit-Taking Pressure Emerges After 295% Year-to-Date Rally

Market Focus08-14 22:58

On August 14, Twist Bioscience Corp declined 5.36% in regular trading, trading at $119.06/share, with turnover of $57.72 million.

The pullback comes amid profit-taking pressure following a roughly 295% year-to-date surge driven by the AI-enabled drug discovery narrative. The company reported fiscal Q3 results on August 3 showing EPS of -$0.56, missing the consensus estimate of -$0.50, though revenue of $118.4 million beat expectations of $114.5 million. Q4 revenue guidance of $123M-$124M also exceeded the FactSet estimate of $117.4M. Despite strong revenue momentum and the approaching adjusted EBITDA breakeven milestone, market commentators have flagged the need for maintaining safety margins when chasing elevated valuations, warning investors to prioritize cash flow delivery over narrative momentum in high-volatility names.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1180484644?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-14 22:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180484644","market":"us","top_or_hot":-1,"title":"Movement Alert｜Twist Bioscience Corp Falls 5.36% in Regular Trading, Profit-Taking Pressure Emerges After 295% Year-to-Date Rally","media":"Market Focus","content":"<p><p>On August 14, Twist Bioscience Corp declined 5.36% in regular trading, trading at $119.06/share, with turnover of $57.72 million.</p><p>The pullback comes amid profit-taking pressure following a roughly 295% year-to-date surge driven by the AI-enabled drug discovery narrative. The company reported fiscal Q3 results on August 3 showing EPS of -$0.56, missing the consensus estimate of -$0.50, though revenue of $118.4 million beat expectations of $114.5 million. Q4 revenue guidance of $123M-$124M also exceeded the FactSet estimate of $117.4M. Despite strong revenue momentum and the approaching adjusted EBITDA breakeven milestone, market commentators have flagged the need for maintaining safety margins when chasing elevated valuations, warning investors to prioritize cash flow delivery over narrative momentum in high-volatility names.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Twist Bioscience Corp Falls 5.36% in Regular Trading, Profit-Taking Pressure Emerges After 295% Year-to-Date Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Twist Bioscience Corp Falls 5.36% in Regular Trading, Profit-Taking Pressure Emerges After 295% Year-to-Date Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-14 22:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 14, Twist Bioscience Corp declined 5.36% in regular trading, trading at $119.06/share, with turnover of $57.72 million.</p><p>The pullback comes amid profit-taking pressure following a roughly 295% year-to-date surge driven by the AI-enabled drug discovery narrative. The company reported fiscal Q3 results on August 3 showing EPS of -$0.56, missing the consensus estimate of -$0.50, though revenue of $118.4 million beat expectations of $114.5 million. Q4 revenue guidance of $123M-$124M also exceeded the FactSet estimate of $117.4M. Despite strong revenue momentum and the approaching adjusted EBITDA breakeven milestone, market commentators have flagged the need for maintaining safety margins when chasing elevated valuations, warning investors to prioritize cash flow delivery over narrative momentum in high-volatility names.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TWST","symbol_name":"Twist Bioscience Corp","start_time":0,"source_url":"","article_id":"1180484644","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180484644","pubTimestamp":1786719528,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 14, Twist Bioscience Corp declined 5.36% in regular trading, trading at $119.06/share, with turnover of $57.72 million.The pullback comes amid profit-taking pressure following a roughly...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TWST":"Twist Bioscience Corp"},"translate_title":"走势警报|Twist Bioscience Corp 常规交易下跌 5.36%，年初至今上涨 295% 后出现获利了结压力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TWST":1},"content_text":"On August 14, Twist Bioscience Corp declined 5.36% in regular trading, trading at $119.06/share, with turnover of $57.72 million.The pullback comes amid profit-taking pressure following a roughly 295% year-to-date surge driven by the AI-enabled drug discovery narrative. The company reported fiscal Q3 results on August 3 showing EPS of -$0.56, missing the consensus estimate of -$0.50, though revenue of $118.4 million beat expectations of $114.5 million. Q4 revenue guidance of $123M-$124M also exceeded the FactSet estimate of $117.4M. Despite strong revenue momentum and the approaching adjusted EBITDA breakeven milestone, market commentators have flagged the need for maintaining safety margins when chasing elevated valuations, warning investors to prioritize cash flow delivery over narrative momentum in high-volatility names.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1180484644","isCrawlerRequest":true}